Related Articles by Review for PMID: 37988546

Year	Number of Results
2012	11
2014	1
2015	2
2016	1
2017	1
2018	1
2019	3
2021	6
2022	8
2023	16
2025	0

1

[No authors listed] [No authors listed] 2023 Oct 30. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Oct 30. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 37988546 Free Books & Documents. Review.

2

Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.

Russell MC, Garelli AM, Reeves DJ. Russell MC, et al. Ann Pharmacother. 2023 Feb;57(2):198-206. doi: 10.1177/10600280221098398. Epub 2022 Jun 2. Ann Pharmacother. 2023. PMID: 35652704 Review.

3

Clinical Utility of Mobocertinib in the Treatment of NSCLC - Patient Selection and Reported Outcomes.

Arnold A, Ganti AK. Arnold A, et al. Onco Targets Ther. 2023 Jul 11;16:559-569. doi: 10.2147/OTT.S374489. eCollection 2023. Onco Targets Ther. 2023. PMID: 37456145 Free PMC article. Review.

4

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions.

Imran M, Khan SA, Alshammari MK, Alreshidi MA, Alreshidi AA, Alghonaim RS, Alanazi FA, Alshehri S, Ghoneim MM, Shakeel F. Imran M, et al. Biomedicines. 2021 Dec 17;9(12):1938. doi: 10.3390/biomedicines9121938. Biomedicines. 2021. PMID: 34944754 Free PMC article. Review.

5

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations.

Zhang SS, Zhu VW. Zhang SS, et al. Lung Cancer (Auckl). 2021 Jul 12;12:61-65. doi: 10.2147/LCTT.S307321. eCollection 2021. Lung Cancer (Auckl). 2021. PMID: 34285620 Free PMC article. Review.

6

Mobocertinib in non-small cell lung cancer.

Liu S, Lowder KE. Liu S, et al. Drugs Today (Barc). 2022 Nov;58(11):523-530. doi: 10.1358/dot.2022.58.11.3408816. Drugs Today (Barc). 2022. PMID: 36422513 Review.

7

New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.

David GM, Maria Del Pilar BC, Cristina MR. David GM, et al. J Oncol Pharm Pract. 2023 Jun;29(4):934-943. doi: 10.1177/10781552231162545. Epub 2023 Mar 14. J Oncol Pharm Pract. 2023. PMID: 36916182 Review.

8

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.

Chung C. Chung C. J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8. J Oncol Pharm Pract. 2016. PMID: 25855240 Review.

9

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations.

Low JL, Lim SM, Lee JB, Cho BC, Soo RA. Low JL, et al. Ther Adv Med Oncol. 2023 Jan 27;15:17588359221146131. doi: 10.1177/17588359221146131. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36756143 Free PMC article. Review.

10

Mobocertinib: First Approval.

Markham A. Markham A. Drugs. 2021 Nov;81(17):2069-2074. doi: 10.1007/s40265-021-01632-9. Drugs. 2021. PMID: 34716908 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 37988546

35 results

Results by year